The initiative addresses one of today's most pressing global challenges: Translating promising research into improved care for people living with CMDs. Despite Europe's strong position in CMD research, many promising discoveries fail to progress beyond the academic laboratory.
To address this challenge, a new initiative, CardioMetabolic Bridge, will support selected academic research projects with funding, scientific and commercial mentoring from entrepreneurs and industry experts and access to state-of-the-art facilities. The initiative is backed by up to DKK 450 million (EUR 60.2 million) from the Novo Nordisk Foundation over six years. This month, the initiative's first lab space will be opening in London followed by sister sites in Italy and Germany.
Key Technical Differences
While Waymo holds the advantage of massive, real-world data collection and an operating commercial fleet, Wayve's software-first approach is rapidly gaining ground. Supported by investors like Microsoft, Wayve’s strategy is designed to bypass expensive fleet manufacturing, potentially scaling AI driving to millions of privately-owned consumer vehicles by 2027 and 2028.
